Novel emerging biomarkers to immunotherapy in kidney cancer

The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yasser Ged, Martin H. Voss
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/85f04da038e547b387181e4738d986d2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85f04da038e547b387181e4738d986d2
record_format	dspace
spelling	oai:doaj.org-article:85f04da038e547b387181e4738d986d22021-12-01T23:33:26ZNovel emerging biomarkers to immunotherapy in kidney cancer1758-835910.1177/17588359211059367https://doaj.org/article/85f04da038e547b387181e4738d986d22021-11-01T00:00:00Zhttps://doi.org/10.1177/17588359211059367https://doaj.org/toc/1758-8359The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ultimately require salvage therapies. An ever deeper understanding of the disease biology mediated by the development of multiple high-throughput molecular omics has led to significant progress in biomarkers discovery. But despite growing insights into the molecular underpinnings of the tumor microenvironment, biomarkers have not been integrated successfully into clinical practice. In this review, we discuss some of the novel emerging predictive biomarkers to ICIs in metastatic renal cell carcinoma.Yasser GedMartin H. VossSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTherapeutic Advances in Medical Oncology, Vol 13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yasser Ged Martin H. Voss Novel emerging biomarkers to immunotherapy in kidney cancer
description	The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ultimately require salvage therapies. An ever deeper understanding of the disease biology mediated by the development of multiple high-throughput molecular omics has led to significant progress in biomarkers discovery. But despite growing insights into the molecular underpinnings of the tumor microenvironment, biomarkers have not been integrated successfully into clinical practice. In this review, we discuss some of the novel emerging predictive biomarkers to ICIs in metastatic renal cell carcinoma.
format	article
author	Yasser Ged Martin H. Voss
author_facet	Yasser Ged Martin H. Voss
author_sort	Yasser Ged
title	Novel emerging biomarkers to immunotherapy in kidney cancer
title_short	Novel emerging biomarkers to immunotherapy in kidney cancer
title_full	Novel emerging biomarkers to immunotherapy in kidney cancer
title_fullStr	Novel emerging biomarkers to immunotherapy in kidney cancer
title_full_unstemmed	Novel emerging biomarkers to immunotherapy in kidney cancer
title_sort	novel emerging biomarkers to immunotherapy in kidney cancer
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/85f04da038e547b387181e4738d986d2
work_keys_str_mv	AT yasserged novelemergingbiomarkerstoimmunotherapyinkidneycancer AT martinhvoss novelemergingbiomarkerstoimmunotherapyinkidneycancer
_version_	1718403996096397312

Novel emerging biomarkers to immunotherapy in kidney cancer

Ejemplares similares